Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $682.28M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.16M
Average 0.08M
Balance Sheet
Inspect the capital base behind the business.
Assets
$31.71M
FY 2025 · Annual
+70.4% YoYLiabilities
$13.30M
FY 2025 · Annual
+49.5% YoYEquity
$18.41M
FY 2025 · Annual
+89.6% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $25.1M |
| Other Current | $268.0K |
| Total Current Assets | $25.4M |
| Total Assets | $25.4M |
Analysis
Selected assets total $25.4M for Latest. The largest visible component is Cash & Equivalents at $25.1M, about 98.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| EFFECT | EFFECT filing | Aug 28, 2026 | |
| S-3 | S-3 filing | Aug 21, 2026 | |
| 8-K | Current report | Aug 21, 2026 |
How much cash does NVCT have?
Nuvectis Pharma, Inc. (NVCT) reported $31.63M in cash and equivalents in fiscal 2025.
How much debt does NVCT carry?
Nuvectis Pharma, Inc. (NVCT) reported $0.00 of total debt, with net debt of -$31.63M.
Continue the stock analysis
Jump to another research area for this company.